This novel PPAR-γ agonist and scaffold tuning approach is expected to broaden the bottleneck of new drug discovery for CVD, CML and various types of solid tumors as well as metabolic diseases. Here, PPARG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.